Compare Opendoor Technologies Inc (OPEN) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance

Opendoor (OPEN) trades at $1.99, down 4.78% on the day, reflecting persistent bearish sentiment amid a challenging housing market. The stock shows oversold technical signals with an RSI near 21, while fundamentals reveal steep losses with a net income margin of -46.74% in 2025 and negative ROE of -196.89%. Recent news highlights expansion into mortgages across 35-40 states by end-2026 to drive growth, but earnings misses in Q1 and Q2 2026 underscore execution risks. Cash flow improved in 2025 with net positive $538M, yet 2026 projections show renewed outflows.

The outlook remains cautious; analyst consensus is mixed with 65% hold ratings, but a $4.92 price target implies significant upside if turnaround succeeds. Key risks include interest rate sensitivity, high debt levels, and prolonged profitability challenges. Revenue declines from $15.6B in 2022 to $4.4B in 2025 highlight operational headwinds, making recovery dependent on housing market stabilization and cost controls.

Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.

The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.